These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20406839)

  • 1. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
    Wang S; Ren W; Liu J; Lahat G; Torres K; Lopez G; Lazar AJ; Hayes-Jordan A; Liu K; Bankson J; Hazle JD; Lev D
    Clin Cancer Res; 2010 May; 16(9):2591-604. PubMed ID: 20406839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines.
    Tomek S; Koestler W; Horak P; Grunt T; Brodowicz T; Pribill I; Halaschek J; Haller G; Wiltschke C; Zielinski CC; Krainer M
    Eur J Cancer; 2003 Jun; 39(9):1318-29. PubMed ID: 12763223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
    Ren W; Korchin B; Lahat G; Wei C; Bolshakov S; Nguyen T; Merritt W; Dicker A; Lazar A; Sood A; Pollock RE; Lev D
    Clin Cancer Res; 2008 Sep; 14(17):5466-75. PubMed ID: 18765538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
    Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
    Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
    Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
    Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
    Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of TRAIL and taurolidine on apoptosis and proliferation in human rhabdomyosarcoma, leiomyosarcoma and epithelioid cell sarcoma.
    Karlisch C; Harati K; Chromik AM; Bulut D; Klein-Hitpass L; Goertz O; Hirsch T; Lehnhardt M; Uhl W; Daigeler A
    Int J Oncol; 2013 Mar; 42(3):945-56. PubMed ID: 23338823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma.
    Pasello G; Urso L; Silic-Benussi M; Schiavon M; Cavallari I; Marulli G; Nannini N; Rea F; Ciminale V; Favaretto A
    J Thorac Oncol; 2014 Jul; 9(7):1008-1017. PubMed ID: 24922007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.
    Giacomini A; Righi M; Cleris L; Locatelli SL; Mitola S; Daidone MG; Gianni AM; Carlo-Stella C
    Angiogenesis; 2013 Jul; 16(3):707-22. PubMed ID: 23605004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
    Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
    Ren W; Korchin B; Zhu QS; Wei C; Dicker A; Heymach J; Lazar A; Pollock RE; Lev D
    Clin Cancer Res; 2008 May; 14(9):2785-95. PubMed ID: 18451246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
    Shankar S; Ganapathy S; Srivastava RK
    Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis.
    Wei RJ; Zhang XS; He DL
    Asian J Androl; 2018; 20(2):200-204. PubMed ID: 28869219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.